[Chronic liver disease exacerbated during alpha-interferon treatment].
A 27 year old male patient was referred to our clinical unit because of marked elevation of serum bilirubin (up to 15.3 mg/dl), ASAT (563 U/l) and ALAT (845 U/l) were detected after institution of therapy with alpha interferon. The patient had been previously treated because of persistent slight elevation of serum transaminases, serological markers of hepatitis B virus and hepatitis C virus being both negative. Liver histology was consistent with chronic active hepatitis. Antinuclear, anti smooth muscle and antimitochondrial autoantibodies were all negative, although anti smooth muscle antibodies became positive (1/40) after interferon therapy. The drug was withdrawn, prednisone was instituted, and transaminases and bilirubin values returned to normality.
Rodríguez Moreno
F
F
Departamento de Medicina Interna, Hospital Universitario de Canarias, La Laguna, Tenerife.
González Reimers
C E
CE
Santolaria Fernández
F
F
García Castro
C
C
Martínez Riera
A
A
Batista López
N
N
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D001706:Biopsy; D002908:Chronic Disease; D006505:Hepatitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000175:diagnosis / Q000473:pathology*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects*; D008099:Liver / Q000473:pathology; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood
D000893:Anti-Inflammatory Agents; D016898:Interferon-alpha; D000637:Transaminases; D001663:Bilirubin; D011241:Prednisone
Hepatopatía crónica exacerbada tras tratamiento con alpha-interferón.